title: Alteration of the lipid and apolipoprotein contents of lipoprotein (a) in haemodialysis patients.
abstract: BACKGROUND
  To examine the possible alteration in Lp(a) composition, protein and lipid contents of Lp(a) were determined in 10 haemodialysis patients (HD) matched with 10 controls (C) for apo(a) phenotypes.
  
  
  METHODS
  All subjects (HD and C) had Lp(a) concentrations greater than 30 mg/dl (mean+/-SD : 82.3+/-41.4 vs 49. 3+22.5 mg/dl), a concentration which has been determined to be associated with an elevated cardiovascular risk. Apo(a)-containing particles were isolated by immunoaffinity chromatography using a monoclonal anti-apo(a) antibody.
  
  
  RESULTS
  The molar concentrations of lipid and protein constituents of immunoaffinity isolated Lp(a) were expressed as number of moles per mole of apo(a). Lp(a) from HD patients were significantly richer in apo Cl11 (P<0.05) and triglycerides (TG) (P<0.05), compared to those of controls. Molar ratios of apo B, apo E, cholesterol and phospholipid s per apo(a)-containing particles were in the same range in both groups.
  
  
  CONCLUSIONS
  Lp(a) from HD patients is characterized by an elevated content in TH and apo Cl11 in comparison with those of controls. Further studies are needed to evaluate in HD patients the contribution of changes in Lp(a) composition towards the metabolism of these particles.
authors.affiliation: Laboratoire de Recherches Néphrologiques, Hôpital Calmette, Lille Cédex, France.
authors.forename: V
authors.initials: V
authors.lastname: Hugue
authors.forename: M
authors.initials: M
authors.lastname: Kandoussi
authors.forename: H J
authors.initials: HJ
authors.lastname: Parra
authors.forename: M
authors.initials: M
authors.lastname: Dracon
authors.forename: J C
authors.initials: JC
authors.lastname: Fruchart
authors.forename: A
authors.initials: A
authors.lastname: Tacquet
authors.forename: C
authors.initials: C
authors.lastname: Cachera
mesh_terms: D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D016022:Case-Control Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008055:Lipids / Q000097:blood; D017270:Lipoprotein(a) / Q000097:blood / Q000737:chemistry*; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D001053:Apolipoproteins; D008055:Lipids; D017270:Lipoprotein(a)